Fresenius Kabi
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Women's health
Fresenius Kabi is a clinical trial sponsor. It has 3 active clinical trials with 170 planned participants, across 11 therapeutic areas. Since 2021 it has completed 8 trials and stopped 5 early. Its FDA record on file shows 1 warning letter.
Trial track record · since 2021
FDA record
Recent FDA actions
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
42 approved drug applications with a product on the market.
Questions about Fresenius Kabi
Yes. FDA has published 1 warning letter naming Fresenius Kabi; the latest was posted on 2026-09-29. Each letter links to FDA's own posting.
Fresenius Kabi is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 170 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 8 trials and stopped 5 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Fresenius Kabi; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-14.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Fresenius Kabi.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.